MRI evolution of new MS lesions enhancing after different doses of gadolinium

M. Rovaris; G. Mastronardo; C. Gasperini; F. Prandini; T. A. Yousry; M. Filippi

MRI evolution of new MS lesions enhancing after different doses of gadolinium

M. Rovaris, G. Mastronardo, C. Gasperini, F. Prandini, T. A. Yousry, M. Filippi

Research output: Contribution to journal › Article › peer-review

Abstract

Objective - To investigate the evolution of multiple sclerosis (MS) lesions enhancing after single dose (SD) or triple dose (TD) of gadolinium- DTPA (Gd). Material and methods - For 3 months, 30 relapsing-remitting MS patients underwent 2 monthly MRI sessions, consisting of Gd-enhanced T₁- weighted scans, after SD (i.e., 0.1 mmol/kg) in one session and TD (i.e., 0.3 mmol/kg) in the other. New enhancing lesions on month 1 and month 2 follow- up scans were studied and for them any persistence of enhancement was evaluated on the scans obtained the next month. Results - In all, 151 lesions enhancing after both SD and TD and 91 lesions enhancing only after TD entered the analysis. After 1 month, for the 151 lesions enhancing after both SD and TD, 73 (48%) were not enhancing, 50 (33%) were still enhancing after both SD and TD and 28 (19%) were enhancing only after TD. For the 91 lesions enhancing only after TD, 61 (67%; P

Original language	English
Pages (from-to)	90-93
Number of pages	4
Journal	Acta Neurologica Scandinavica
Volume	98
Issue number	2
Publication status	Published - 1998

Keywords

Blood- brain barrier permeability
Gadolinium-DTPA
Magnetic resonance imaging
Multiple sclerosis

ASJC Scopus subject areas

Clinical Neurology
Neuroscience(all)

Access to Document

Fingerprint Dive into the research topics of 'MRI evolution of new MS lesions enhancing after different doses of gadolinium'. Together they form a unique fingerprint.

Cite this

@article{dede06a9384b4583989b91e62b2148b7,

title = "MRI evolution of new MS lesions enhancing after different doses of gadolinium",

abstract = "Objective - To investigate the evolution of multiple sclerosis (MS) lesions enhancing after single dose (SD) or triple dose (TD) of gadolinium- DTPA (Gd). Material and methods - For 3 months, 30 relapsing-remitting MS patients underwent 2 monthly MRI sessions, consisting of Gd-enhanced T1- weighted scans, after SD (i.e., 0.1 mmol/kg) in one session and TD (i.e., 0.3 mmol/kg) in the other. New enhancing lesions on month 1 and month 2 follow- up scans were studied and for them any persistence of enhancement was evaluated on the scans obtained the next month. Results - In all, 151 lesions enhancing after both SD and TD and 91 lesions enhancing only after TD entered the analysis. After 1 month, for the 151 lesions enhancing after both SD and TD, 73 (48%) were not enhancing, 50 (33%) were still enhancing after both SD and TD and 28 (19%) were enhancing only after TD. For the 91 lesions enhancing only after TD, 61 (67%; P",

keywords = "Blood- brain barrier permeability, Gadolinium-DTPA, Magnetic resonance imaging, Multiple sclerosis",

author = "M. Rovaris and G. Mastronardo and C. Gasperini and F. Prandini and Yousry, {T. A.} and M. Filippi",

year = "1998",

language = "English",

volume = "98",

pages = "90--93",

journal = "Acta Neurologica Scandinavica",

issn = "0001-6314",

publisher = "Wiley Blackwell",

number = "2",

}

TY - JOUR

T1 - MRI evolution of new MS lesions enhancing after different doses of gadolinium

AU - Rovaris, M.

AU - Mastronardo, G.

AU - Gasperini, C.

AU - Prandini, F.

AU - Yousry, T. A.

AU - Filippi, M.

PY - 1998

Y1 - 1998

N2 - Objective - To investigate the evolution of multiple sclerosis (MS) lesions enhancing after single dose (SD) or triple dose (TD) of gadolinium- DTPA (Gd). Material and methods - For 3 months, 30 relapsing-remitting MS patients underwent 2 monthly MRI sessions, consisting of Gd-enhanced T1- weighted scans, after SD (i.e., 0.1 mmol/kg) in one session and TD (i.e., 0.3 mmol/kg) in the other. New enhancing lesions on month 1 and month 2 follow- up scans were studied and for them any persistence of enhancement was evaluated on the scans obtained the next month. Results - In all, 151 lesions enhancing after both SD and TD and 91 lesions enhancing only after TD entered the analysis. After 1 month, for the 151 lesions enhancing after both SD and TD, 73 (48%) were not enhancing, 50 (33%) were still enhancing after both SD and TD and 28 (19%) were enhancing only after TD. For the 91 lesions enhancing only after TD, 61 (67%; P

AB - Objective - To investigate the evolution of multiple sclerosis (MS) lesions enhancing after single dose (SD) or triple dose (TD) of gadolinium- DTPA (Gd). Material and methods - For 3 months, 30 relapsing-remitting MS patients underwent 2 monthly MRI sessions, consisting of Gd-enhanced T1- weighted scans, after SD (i.e., 0.1 mmol/kg) in one session and TD (i.e., 0.3 mmol/kg) in the other. New enhancing lesions on month 1 and month 2 follow- up scans were studied and for them any persistence of enhancement was evaluated on the scans obtained the next month. Results - In all, 151 lesions enhancing after both SD and TD and 91 lesions enhancing only after TD entered the analysis. After 1 month, for the 151 lesions enhancing after both SD and TD, 73 (48%) were not enhancing, 50 (33%) were still enhancing after both SD and TD and 28 (19%) were enhancing only after TD. For the 91 lesions enhancing only after TD, 61 (67%; P

KW - Blood- brain barrier permeability

KW - Gadolinium-DTPA

KW - Magnetic resonance imaging

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=0031858174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031858174&partnerID=8YFLogxK

M3 - Article

C2 - 9724005

AN - SCOPUS:0031858174

VL - 98

SP - 90

EP - 93

JO - Acta Neurologica Scandinavica

JF - Acta Neurologica Scandinavica

SN - 0001-6314

IS - 2

ER -